Table 1.

H929-60 cells are not resistant to standard myeloma therapies

CompoundH929 IC50 (n = 3)H929-60 IC50 (n = 3)
Melphalan11.3 ± 2.5 μmol/L13.1 ± 3.7 μmol/L
Mitoxantrone1.42 ± 0.4 μmol/L1.05 ± 0.7 μmol/L
Bortezomib11.3 ± 5.1 nmol/L12.2 ± 3.9 nmol/L

NOTE: H929 and H929-60 cells were treated with increasing concentrations of melphalan, mitoxanthrone, or bortezomib for 24 hours. After 24 hours, cells were stained with annexin V–fluorescein isothiocyanate/propidium iodide for 45 minutes and acquired on FACScan. IC50 values were determined by linear regressions. Shown is the mean and SDs of 3 independent experiments.